Phase II Study of Erlotinib as Third-line Monotherapy in Patients with Advanced Non-small-cell Lung Cancer without Epidermal Growth Factor Receptor Mutations

Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib

(2011) Vince D. Cataldo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis

(2010) Luis Paz-Ares et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Third-Line Chemotherapy in Advanced Non-small Cell Lung Cancer: Identifying the Candidates for Routine Practice

(2010) Nicolas Girard et al.   Journal of Thoracic Oncology

A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non-small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations: Okayama Lung Cancer Study Group Trial 0705

(2010) Hiroshige Yoshioka et al.   Journal of Thoracic Oncology

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

(2010) Federico Cappuzzo et al.   LANCET ONCOLOGY

The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer

(2010) Myung Hee Chang et al.   LUNG CANCER

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Second and third line treatment in non-small cell lung cancer

(2009) Adolfo Favaretto et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

(2009) Christopher G. Azzoli et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial

(2009) Jean-Yves Douillard et al.   JOURNAL OF CLINICAL ONCOLOGY

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

(2009) Rafael Rosell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Role ofKRASandEGFRAs Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21

(2008) Chang-Qi Zhu et al.   JOURNAL OF CLINICAL ONCOLOGY